Citigroup initiated coverage on Avidity Biosciences with a new price target
$RNA
Biotechnology: Pharmaceutical Preparations
Health Care
Citigroup initiated coverage of Avidity Biosciences with a rating of Buy and set a new price target of $70.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/13/2025 | $70.00 | Buy | Citigroup |
| 3/12/2025 | $72.00 | Outperform | BMO Capital Markets |
| 3/7/2025 | $70.00 | Sector Outperform | Scotiabank |
| 12/20/2024 | $72.00 | Buy | H.C. Wainwright |
| 11/26/2024 | $67.00 | Outperform | RBC Capital Mkts |
| 9/24/2024 | $59.00 | Buy | Goldman |
| 8/28/2024 | $63.00 | Overweight | Barclays |
| 5/3/2024 | $40.00 | Buy | BofA Securities |
Aravindhan Veerapandiyan, MD, Associate Professor of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital and EXPLORE44® trial investigator, will present topline del-zota data from Phase 1/2 EXPLORE44 trial at 2025 MDA Clinical & Scientific Conference in Dallas, Texas Avidity to host investor and analyst webcast event March 17, 2025, at 8:00 a.m. ET Key opinion leaders to participate in Avidity sponsored industry forum event "Advancing RNA Therapeutics", March 17, 2025, at 7:00 a.m. CT/8:00 a.m. ET SAN DIEGO, March 12, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therap
SAN DIEGO, Feb. 28, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it is joining the global community of patients, caregivers, families and healthcare providers to build broader awareness of rare diseases, including rare neuromuscular diseases, and the urgent need for more approved treatments for many of these conditions in support of Rare Disease Day®. "Rare Disease Day represents an important opportunity for al
Building on success across its three clinical programs, Avidity is leading in rare neuromuscular diseases with a strong balance sheet to execute on a transformational 2025 Major milestones anticipated for each rare neuromuscular program in 2025, including preparing for Avidity's first BLA submission Commercial preparations well underway in anticipation of three potential successive product launches for DMD, DM1 and FSHD starting in 2026 Phase 1/2 EXPLORE44® top-line del-zota data to be presented at the 2025 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in Dallas, Texas SAN DIEGO, Feb. 27, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceut
Discussions with the FDA ongoing as Avidity submits emerging AOC 1001 data from the MARINA trial AOC 1001 continues to be generally well tolerated; Avidity provides more information on the rare serious adverse event in a single participant that led to the partial clinical hold AOC 1001 top-line safety and functional data to be presented at the American Academy of Neurology (AAN) Annual Meeting on April 27, 2023 Avidity to hold a webcast/conference call today at 8:00 a.m. ET/5:00 a.m. PT SAN DIEGO, March 30, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates
Participants currently enrolled in MARINA and MARINA-OLE™ trials may continue to be treated with AOC 1001 Avidity received Investigational New Drug (IND) clearance for FSHD and DMD studies from FDA; programs now advancing into the clinic Company to host investor webcast today at 8:30 a.m. ET / 5:30 a.m. PT SAN DIEGO, Sept. 27, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on new participant enrollment in the Phase 1/2 MARINA™ clinical trial of A
Citigroup initiated coverage of Avidity Biosciences with a rating of Buy and set a new price target of $70.00
BMO Capital Markets initiated coverage of Avidity Biosciences with a rating of Outperform and set a new price target of $72.00
Scotiabank initiated coverage of Avidity Biosciences with a rating of Sector Outperform and set a new price target of $70.00
4 - Avidity Biosciences, Inc. (0001599901) (Issuer)
4 - Avidity Biosciences, Inc. (0001599901) (Issuer)
4 - Avidity Biosciences, Inc. (0001599901) (Issuer)
– Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry
SAN DIEGO, Aug. 5, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of John B. Moriarty, Jr., J.D., as Chief Legal Officer and Corporate Secretary, effective immediately. With almost 30 years of industry experience, Mr. Moriarty brings extensive legal expertise and a proven track record of successfully guiding leading global biotech companies through transformational growth. Mr. Moriarty succeeds Joh
Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut
144 - Avidity Biosciences, Inc. (0001599901) (Subject)
S-8 - Avidity Biosciences, Inc. (0001599901) (Filer)
10-K - Avidity Biosciences, Inc. (0001599901) (Filer)
SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)
SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)
SC 13G - Avidity Biosciences, Inc. (0001599901) (Subject)